Eli Lilly recently announced that a key patient accessibility program will be launched soon.

From July 1, 2026, eligible Medicare beneficiaries will be able to access the medication Foundayo through a new program called “Medicare GLP-1 Bridge,” with a fixed monthly out-of-pocket cost set at $50. This initiative aims to significantly reduce the financial burden for elderly individuals and certain groups with disabilities, paving the way for them to obtain innovative treatment options. By establishing a predictable and relatively low fixed out-of-pocket payment, the program is expected to enhance the accessibility and adherence to medication. Market analysts believe this may not only provide Eli Lilly with a more stable patient base but also strengthen its product’s market position in the highly competitive GLP-1 receptor agonist market.